semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Giant Axonal Neuropathy Clinical diagnosis of Giant Axonal Neuropathy. 2. Documentation of the presence of a mutation in the GAN gene as determined by gene sequencing from a CAP/CLIA certified laboratory or an equivalent organization. 3. Parents or if applicable subjects must give informed consent must be capable of complying with the study procedures. 4. Willing and able to comply with all protocol requirements and procedures  Unwilling or unable to travel to Columbia University Medical Center. 2. Unstable medical condition precluding participation. 3. Significant respiratory compromise that would interfere with safe travel to site of evaluation. 4. Having a contraindication to the MRI safety requirements, including pacemaker or other implanted electrical device, brain stimulator, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), implanted delivery pump, shrapnel fragments, or history of claustrophobia
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Smoking Dependence Smoking Current cigarette smokers who have smoked regularly, and smoke more than 20 cigarettes per day on a regular basis for at least a year Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history  Any disease that may interfere with the absorption, metabolism or excretion of the study product A medical condition that might jeopardise the safety of the subject or the validity of the study results. For example, recent myocardial infarction or cerebrovascular incident (within 12 weeks of the screening visit), phenylketonuria, unstable or worsening angina pectoris, Prinzmetals angina or severe cardiac arrhythmia
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-68.0,  Relapsing-Remitting Multiple Sclerosis Relapsing remitting MS Stable immunomodulatory treatment or no treatment at least 6 months prior to Expanded disability status scale < 7 Body mass index (BMI) > or = 18,5 OR BMI > or = 45 with no risk factors Not pregnant or breast-feeding No serious mental health illness such as dementia or schizophrenia No use of a weight loss therapy in the month prior to screening  Start or changes if immunomodulatory treatment < 7 months prior to screening SPMS or PPMS Relapse or corticosteroid use < 30 days prior to screening Diabetes or any metabolic defects Bulimia Anorexia Drug abuse
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Multiple Sclerosis Age 45 years or older of either gender and of any racial/ethnic group. 2. Subjects must be in generally good health. 3. Subjects must be able and willing to comply with the requirements of the protocol. 4. Must be diagnosed with RRMS 5. Meets the to enter Group 1 or Group 2  Subject is currently in middle of an active episode of an autoimmune condition (e.g. rheumatoid arthritis, system lupus erythematosis) 2. Subject currently has a condition such as active influenza that would stimulate the immune system
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Relapsing Remitting Multiple Sclerosis Diagnosis of clinically definite relapsing remitting MS (RRMS) 2. Age 45 years and older 3. Willing and able to provide written informed consent 4. Patient has high disease activity. 5. Patient is about to begin Natalizumab (Tysabri) therapy  Any clinically significant disease other than MS that is likely to interfere with the evaluation of CDMS 2. Known infectious or hematological disease. 3. Unwilling or unable to comply with the requirements of this protocol 4. Subject can not have a gadolinium enhanced MRI
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Scar Ages 50 (Both Male & Female) Non-smoker having quit at least 3 months prior to enrollment Non-diabetic Non-pregnant or non-breastfeeding verbal assent If a female subject of childbearing age misses her menstrual period after the start of the study, she will inform the investigators and be given a pregnancy test to ensure, for safety reasons, that she is not pregnant. If she is pregnant, she will discontinue participation in the study No current use of OTC medications or other form of supplements containing vitamin-E  Diabetes or HIV diagnosis Alcohol or drug abuse unable to provide informed consent Therapeutically anti-coagulated Prisoner Currently prescribed immunosuppressant medication
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Neurological Disorders Cerebral Malaria Bacterial Meningitis Central Nervous System Tuberculosis Neurosyphilis Cryptococcal Meningitis Patients > 5 years-old AND Altered state of consciousness (confusion to coma) OR/AND Changes of sleep pattern (daytime slumber, night insomnia)OR/AND Cognitive decline OR/AND Changes in personality/behaviour (e.g. bouts of mania)OR/AND Epileptic seizure(s)OR/AND Daily severe/progressive headache OR/AND Meningismus (headache, neck stiffness, nausea/vomiting, photophobia) Cranial nerve lesions OR/AND Sensory-motor deficits or other focal neurological signs (e.g. dysphagia, dysarthria, ataxia, dystonia,...)OR/AND  Those unwilling or unable to give written informed consent (either directly or via proxy) Those unable in the physician's opinion to comply with the study requirements Neurological symptom unequivocally related with recent trauma Neurological symptom as sequelae of previous well-established neurological events (e.g. stroke,…) First seizure below 6 years of age (early onset seizure)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 50.0-90.0,  Alzheimer's Disease Mild Cognitive Impairment Frontotemporal Dementia years of age or older (50 years of age or older for frontotemporal dementia patients) Normal memory, mild cognitive impairment (memory loss that does not significantly affect normal daily activities), or clinical diagnosis of Alzheimer's disease or frontotemporal dementia (includes primary progressive aphasia) Right-handed General good physical health  History of stroke or neurological disease (other than Alzheimer's disease or frontotemporal dementia) Seizures or head injury with loss of consciousness within the last five years Ferrous (magnetic) or electronic implants (due to the magnet in the MRI scanner) Claustrophobia
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis, Relapsing-remitting Enrolled into the 2-year, double-blind, placebo-controlled ASA study and entered 3 year extension study MRI was performed on all patients using a 1.5 T magnet  MRI images unable to be processed All 5 MRI time points not collected
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Acne Vulgaris Subject is male or non-pregnant female. Females must be post-menopausal, surgically sterile or using highly effective birth control methods Subject has provided written and verbal informed consent/assent Subject has facial acne vulgaris (including the nose) Subject is willing to comply with study instructions and return to the clinic for required visits Subject has used the same type and brand of make-up, other facial products (including cleanser) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the study start and agrees to continue his/her other general skin and hair care products and regimen for the entire study  Subject is pregnant, lactating, or is planning to become pregnant during the study Subject is currently enrolled in an investigational drug or device study Subject has received an investigational drug or been treated with an investigational device within 30 days prior to the study start Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial Subject has used any of the following topical anti-acne preparations or procedures on the face Topical anti-acne treatments including but not limited to over-the-counter acne cleaners or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based products, corticosteroids and salicylic acid within two weeks of the initiation of treatment Retinoids, including tazarotene, adapalene, tretinoin, within four weeks of the initiation of treatment Light treatments, microdermabrasion or chemical peels within eight weeks of the initiation of treatment Subject has used the following systemic anti-acne medications Corticosteroids (including intramuscular and intralesional injections) within four weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least four weeks prior to the initiation of treatment)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis Four groups of subjects will be included patients with a RRMS evolving since less than 5 years (revised Mc Donald n=20) patients with a RRMS evolving since more than 5 years and less than 10 years (n=20) patients with a primary progressive MS (PPMS) evolving since less than 10 years (n=20) Healthy volunteers matched for age and sex (2/3 matched with RRMS patients; 1/3 matched with PPMS patients)  Lack of social insurance Pregnancy Age > 55 Therapy with benzodiazepine
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Multiple Sclerosis Age between 18-60, inclusive Patients carry a diagnosis of multiple sclerosis, according to the McDonald's for diagnosis (Polman et al, 2011). Must have a neurologist providing the primary care for the MS and be willing to be evaluated for the multiple sclerosis by the two neurologists who are the co-investigators in the protocol. Must be documented to be HIV negative. An EDSS of 3.5 5 Patients must be able to give written consent. Inflammatory disease despite primary disease modifying therapy with at least 6 months of interferon and another disease modifying therapy, including fingolimod,glativamir, natalizumab, and mitoxantrone. Failure is defined as two or more clinical relapses with documented neurologic changes (excluding sensory changes) within the year prior to the study. (NOTE: Relapses must have required treatment with corticosteroids). Failure may also be defined as one relapse (excluding sensory changes) treated with methylprednisone and, on a separate occasion within the previous 12 months, evidence of active inflammation (i.e. gadolinium enhancement on MRI scan of the CNS). No previous history of allergic reaction to cyclophosphamide, G-CSF or mesna Patients must not be pregnant Failure to accept or comprehend irreversible sterility as a potential side effect of therapy. Life expectancy of more than 6 months No evidence of myelodysplastic syndrome on peripheral blood smear Not allergic to cyclophosphamide, mesna, fludarabine or alemtuzumab Baseline serum creatinine must be <1.5 mg/dL, left ventricular ejection fraction >55%, adequate pulmonary functions (oxygen saturation at room air of >90%), and AST and ALT not > 2x upper limits of normal, and no history of previous or active malignancy, except for localized cutaneous basal or squamous cell carcinoma in situ of the cervix  Diagnosis of primary progressive MS
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 8.0-999.0,  Dysarthria Down Syndrome Adults and children with Downs Syndrome and dysarthria Ages 8 years and older Ability to verbally communicate; follow simple commands and/or imitate others; hear speech at a conversational level; and participate in assessment and speech sessions activities  Additional serious medical problems which prevent meaningful participation in the study